It’s Coming Home: ImmunoACT Advances Plans For Cut-Price CAR-T In India

Citeline Podcasts

English - June 30, 2022 00:20 - 32 minutes - 18.7 MB - ★★★★★ - 24 ratings
Business News Business News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: The Push For OTC Birth Control With Victoria Nichols

Next Episode: Scrip’s Five Must-Know Things – 4 July 2022

ImmunoACT CEO Dr Rahul Purwar outlines progress made by the firm’s early-stage CAR-T therapy in India, which he believes can be available at a tenth of the price of current on-market treatments or around the cost range for bone marrow transplant. Laurus Labs, which holds about 27% in ImmunoACT, is expected to help shape the firm’s globalization plans.

https://scrip.pharmaintelligence.informa.com/SC146616/Whats-Next-At-Dr-Reddys-Biologics-CDMO-Cell-And-Gene-Therapy-Push
https://scrip.pharmaintelligence.informa.com/SC125979/Early-Indian-Promise-For-A-Cut-Price-CAR-T-Therapy
https://scrip.pharmaintelligence.informa.com/SC125879/Gene-And-Cell-Therapies-In-Asia-Indian-Environment-Evolving-But-Multiple-Issues-Unresolved
https://scrip.pharmaintelligence.informa.com/SC144368/Dr-Reddys-Pilots-Sputnik-V-Soft-Launch-In-India-Explores-CART-Space